Overview

Not every patient with lung cancer responds to the same medicine, which is why biomarker-defined subgroups now guide treatment from the start. The 20-gene lung NGS panel is built to find the populations most likely to benefit from targeted options. By covering the drivers seen most often in clinical practice, it turns a diagnosis into a precise, subgroup-aware plan.

How It Works

Hybrid-capture library preparation sequences twenty lung-relevant genes from a single nucleic-acid extract, enabling both small variants and gene rearrangements to be called in one run. The platform reports fusion partners such as ALK and ROS1 alongside point mutations in EGFR, KRAS, and BRAF. Bioinformatic classification then tags each finding with population relevance, so the clinician can see at a glance which approved or emerging pathway a result points to.

Indications

The panel is appropriate for patients with advanced non-small cell lung cancer, especially adenocarcinoma and those with minimal smoking history where driver rates are higher. It is also useful for younger patients and for cases where rapid targeted-therapy matching is a priority. Results help route patients into the correct genotype-defined treatment pathway rather than a one-size approach.

Specimen & Reporting

Either a tissue biopsy or a cytology sample with adequate tumor content can be used, and the report groups findings by actionable population. Standard turnaround is about 7–12 working days. When tissue is limited, the captured design maximizes information from a small input.

Storage & Sourcing

Extracts are stored frozen and shipped on dry ice, while FFPE scrolls travel with desiccant at ambient temperature. Distributors serving multiple clinics can consolidate specimens to reduce logistics overhead. Give Life Time International offers steady supply and reorder support so high-volume centers keep subgroup testing running without interruption.

FAQ

Q: Which patient groups gain the most from this 20-gene panel? Adenocarcinoma, never-smokers, and younger patients show higher driver prevalence and therefore the greatest chance of matching a targeted option.

Q: Does the panel detect both mutations and fusions? Yes. Hybrid capture reports point mutations and structural rearrangements such as ALK or ROS1 fusions from one library.

Q: How are results linked to a treatment population? Each variant is annotated with its associated pathway and the patient subgroup known to respond, supporting subgroup-based therapy choice.

Q: Is a fresh biopsy required, or can archived tissue be used? Archived FFPE blocks are acceptable when tumor content is sufficient, avoiding the need for a repeat invasive procedure.